[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"stock-detail-ARMP":3,"homepage-market-summary":30,"stock-news-ARMP":173},{"ticker":4,"date":5,"profile":6,"quote":14},"ARMP","2026-10-02",{"name":7,"exchange":8,"sector":9,"industry":10,"description":11,"ceo":9,"employees":12,"headquarters":13,"founded":9},"Armata Pharmaceuticals, Inc. Common Stock","NYSE American",null,"BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)","Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.","61","Los Angeles, CA",{"close":15,"open":16,"high":17,"low":18,"prev_close":19,"change":20,"percent_change":21,"volume":22,"transactions":23,"vwap":24,"high_52w":25,"low_52w":26,"avg_volume_52w":27,"range_52w_percent":28,"record_count":29},3.52,3.4,3.55,3.32,3.31,0.21,6.34,123849.263394,1417,3.4925,1960000,0.82999998,15925.772639023324,0,8146,{"status":31,"indices":32,"watchlist":77,"sectors":99,"benchmarks":155},"success",[33,41,48,55,62,69],{"symbol":34,"name":35,"price":36,"change":37,"pct_change":38,"is_up":39,"sparkline":40,"date":5},"SPX","S&P 500",7722.72,56.27,0.73,true,"0.0,5.0 2.3,8.0 4.6,10.4 6.9,13.4 9.3,9.1 11.6,11.5 13.9,13.8 16.2,16.0 18.5,10.3 20.8,9.5 23.2,2.0 25.5,2.0 27.8,5.9 30.1,6.0 32.4,3.4 34.7,7.3 37.1,8.2 39.4,9.4 41.7,8.5 44.0,4.8",{"symbol":42,"name":43,"price":44,"change":45,"pct_change":46,"is_up":39,"sparkline":47,"date":5},"NDX","NASDAQ 100",30807.93,306.37,1,"0.0,11.5 2.3,11.7 4.6,12.4 6.9,14.8 9.3,12.8 11.6,14.6 13.9,16.0 16.2,15.9 18.5,12.2 20.8,10.7 23.2,4.4 25.5,2.6 27.8,4.5 30.1,4.5 32.4,3.5 34.7,6.0 37.1,5.5 39.4,5.0 41.7,4.3 44.0,2.0",{"symbol":49,"name":50,"price":51,"change":52,"pct_change":53,"is_up":39,"sparkline":54,"date":5},"DJI","DOW JONES",51177,250,0.49,"0.0,2.0 2.3,5.5 4.6,7.8 6.9,9.5 9.3,6.7 11.6,7.5 13.9,9.4 16.2,12.9 18.5,11.1 20.8,11.7 23.2,9.6 25.5,10.7 27.8,12.6 30.1,13.5 32.4,10.8 34.7,12.8 37.1,13.5 39.4,16.0 41.7,15.9 44.0,14.5",{"symbol":56,"name":57,"price":58,"change":59,"pct_change":60,"is_up":39,"sparkline":61,"date":5},"COMP","NASDAQ Composite",27190.86,319.27,1.19,"0.0,10.2 2.3,11.1 4.6,13.0 6.9,14.9 9.3,12.1 11.6,13.7 13.9,16.0 16.2,16.0 18.5,11.1 20.8,10.0 23.2,3.4 25.5,2.0 27.8,5.4 30.1,5.4 32.4,3.9 34.7,6.7 37.1,6.9 39.4,6.2 41.7,6.1 44.0,2.6",{"symbol":63,"name":64,"price":65,"change":66,"pct_change":67,"is_up":39,"sparkline":68,"date":5},"RUT","RUSSELL 2000",2815.2,25,0.9,"0.0,2.0 2.3,3.0 4.6,6.1 6.9,8.4 9.3,7.5 11.6,8.8 13.9,10.4 16.2,11.3 18.5,10.2 20.8,11.2 23.2,10.1 25.5,8.8 27.8,12.9 30.1,13.1 32.4,12.8 34.7,14.4 37.1,15.1 39.4,16.0 41.7,15.1 44.0,13.2",{"symbol":70,"name":71,"price":72,"change":73,"pct_change":74,"is_up":75,"sparkline":76,"date":5},"VIX","CBOE VIX",15.31,-1.08,-6.59,false,"0.0,14.8 2.3,10.2 4.6,7.3 6.9,2.0 9.3,9.7 11.6,4.9 13.9,4.5 16.2,2.5 18.5,11.3 20.8,13.7 23.2,13.5 25.5,16.0 27.8,12.3 30.1,10.4 32.4,13.5 34.7,8.8 37.1,8.9 39.4,7.8 41.7,7.6 44.0,11.8",[78,85,92],{"symbol":79,"name":80,"price":81,"change":82,"pct_change":83,"is_up":39,"sparkline":84,"date":5},"NVDA","NVIDIA Corp",233.95,3.09,1.34,"0.0,16.0 7.3,15.3 14.7,9.6 22.0,12.1 29.3,10.3 36.7,6.6 44.0,2.0",{"symbol":86,"name":87,"price":88,"change":89,"pct_change":90,"is_up":39,"sparkline":91,"date":5},"AAPL","Apple Inc",333.69,3.37,1.02,"0.0,8.2 7.3,2.0 14.7,5.2 22.0,16.0 29.3,11.7 36.7,14.9 44.0,10.9",{"symbol":93,"name":94,"price":95,"change":96,"pct_change":97,"is_up":39,"sparkline":98,"date":5},"TSLA","Tesla Inc",370.59,16.48,4.65,"0.0,2.0 7.3,5.3 14.7,13.4 22.0,16.0 29.3,14.9 36.7,15.3 44.0,6.1",[100,105,110,115,120,125,130,135,140,145,150],{"name":101,"etf":102,"change":103,"price":104,"is_up":39},"Technology","XLK",1.01,199.81,{"name":106,"etf":107,"change":108,"price":109,"is_up":39},"Financials","XLF",0.06,53.49,{"name":111,"etf":112,"change":113,"price":114,"is_up":75},"Healthcare","XLV",-0.01,166.18,{"name":116,"etf":117,"change":118,"price":119,"is_up":39},"Consumer Cycl","XLY",1.13,110.04,{"name":121,"etf":122,"change":123,"price":124,"is_up":39},"Consumer Staples","XLP",0.25,80.53,{"name":126,"etf":127,"change":128,"price":129,"is_up":39},"Energy","XLE",0.4,62.95,{"name":131,"etf":132,"change":133,"price":134,"is_up":39},"Industrials","XLI",0.78,169.95,{"name":136,"etf":137,"change":138,"price":139,"is_up":39},"Materials","XLB",0.66,48.86,{"name":141,"etf":142,"change":143,"price":144,"is_up":39},"Real Estate","XLRE",0.32,40.81,{"name":146,"etf":147,"change":148,"price":149,"is_up":39},"Utilities","XLU",0.38,39.83,{"name":151,"etf":152,"change":153,"price":154,"is_up":39},"Comm Services","XLC",0.35,110.32,[156,161,165,169],{"ticker":157,"name":158,"price":159,"change":160,"is_up":39},"SPY","SPDR S&P 500 ETF",769.64,0.74,{"ticker":162,"name":163,"price":164,"change":90,"is_up":39},"QQQ","Invesco QQQ Trust",749.58,{"ticker":166,"name":167,"price":168,"change":53,"is_up":39},"DIA","SPDR Dow Jones ETF",511.1,{"ticker":170,"name":171,"price":172,"change":67,"is_up":39},"IWM","iShares Russell 2000",281.52,{"ticker":4,"count":174,"articles":175},8,[176,182,188,194,200,205,211,216],{"title":177,"link":178,"pubDate":179,"description":180,"source":181},"Armata Pharmaceuticals (ARMP) Secures $3.7M in Non-Dilutive Funding to Advance Phase 3 Trials - GuruFocus","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMixgFBVV95cUxOS3RfMllnNmJxWEpBT0JYVm1FRmpXX0owQlZxUFphRkhOdGVHc1JEdHByV09oNGY2ZFFLZ3phckdILVBsNmVsSE9DSzZ3RllzOXlJdG5PYl9BM3daUjdmaXllVVRtWFdnQlZfbzF5N0lqTXdhWHh4TUNUOC0tZGRROHhXVExRc1Y4djdjYWZERndOSzZCd3c1SW8tME9Hb09nNVN6UjhxUWpEM1dBOS0ybkFaaTVIa3JHRDI5VHFyVlBqR3Q4S0E?oc=5","Wed, 23 Sep 2026 07:00:00 GMT","Armata Pharmaceuticals (ARMP) Secures $3.7M in Non-Dilutive Funding to Advance Phase 3 Trials GuruFocus","GuruFocus",{"title":183,"link":184,"pubDate":185,"description":186,"source":187},"Armata Pharmaceuticals Inc (ARMP-A) Stock Price and News - The Globe and Mail","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMib0FVX3lxTE5neUx0VV9NNnQ3RmhTZ3VwalJYak0tUFVMamd1WnZXQUJsTlM4OTV5c0wxV0tDY2VyczVjRjRmMHI4ZU1MbG9Dd255T29vdFotcXMtaXhrZUR4b3RlbFI0VHhldHNaMTNOYzVjWF82dw?oc=5","Fri, 02 Oct 2026 03:08:19 GMT","Armata Pharmaceuticals Inc (ARMP-A) Stock Price and News The Globe and Mail","The Globe and Mail",{"title":189,"link":190,"pubDate":191,"description":192,"source":193},"(AMEX: ARMP) Share Price, ARMP Stock News, ARMP Share Price & Updates - kalkine.com.au","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiU0FVX3lxTE5WMGIxYTlSSHlnZEV6TXM1UUdvQkZ2ekJGLWJhNGhTTUg2Z25Xc1ZUcmZZSUtfYmVnZUJ4dDdIQmdVaVdWNGFIM3R2UHFNaXB4Q3NF?oc=5","Mon, 28 Sep 2026 23:27:55 GMT","(AMEX: ARMP) Share Price, ARMP Stock News, ARMP Share Price & Updates kalkine.com.au","kalkine.com.au",{"title":195,"link":196,"pubDate":197,"description":198,"source":199},"HC Wainwright & Co. reiterates Buy rating on Armata Pharmaceuticals, $15 price target - TradingView","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMi2gFBVV95cUxPSzc3NlF4Z0pIN2lBMGpPdW9GU3hsbGRZTjUxVXVrYjBOdkJKeW5lVWxMWU1UdHRTQnFfczJVSXFBUDIzY0twaDgtUnRKOWFNRlFIYTYyVmxJdXp6TzJEc3FmVUNvQ2I4YXRfUnpSRTdOU1U4UnlqemtTOE55ZDQ4SEI3ZV9DVnRlRzh1QzlsczQwMGhYUXVrcktjNHpsbXd6Mjh2X2pmbW9XNDBjblU3Q2FxNFpoRDdVaERJcG43UkVjN0NKMVBtelZhRWRNN21URkNoN0Zpd1VWdw?oc=5","Wed, 23 Sep 2026 14:55:00 GMT","HC Wainwright & Co. reiterates Buy rating on Armata Pharmaceuticals, $15 price target TradingView","TradingView",{"title":201,"link":202,"pubDate":203,"description":204,"source":187},"Armata secures new U.S. funding for AP-SA02 Phase 3 - The Globe and Mail","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiywFBVV95cUxOc015cV9Wb1VEUTVjbWVSbjh6RHVCWU01ODNaRHI4R1VpRnZhc0Q5WDJyTHd2QWtlek4yUk9qVkhJdUhpUVYtd0cyNWFOMm5WeGFlSTdkME1obW9rSEZ2WDI5VWZzeldKZk1sTDVkTVpiM01heHZnMmZMb1RhelZSMkhaN0VQM2tCeFR0a2Y3ZHJjQUFaSkdYQjlpZ080dEJWUTJCRWJmUUxCZnVhSXBId0dvY3BvYkdfcko0dGpQS2xtTEYxZm5GTUptWQ?oc=5","Thu, 24 Sep 2026 11:36:00 GMT","Armata secures new U.S. funding for AP-SA02 Phase 3 The Globe and Mail",{"title":206,"link":207,"pubDate":208,"description":209,"source":210},"H.C. Wainwright reiterates Armata Pharmaceuticals stock rating on phage data - Investing.com UK","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMi0AFBVV95cUxNV1NMNmszTG9Hbk9hcmItVHg2Q1lfUDJ1ZURBYUFvdW9RUU1CNzVYamp5Q2U3bkhldV9SSWFvQWV2NHdWaW12NWg3QTBYNWl0STRRTzUyWjcyS3J3Y0xKakdJY2lSSExqdGY3MWwzZU43NmhkQlhSREpvOWpvMzZqaC00OGJ4eVpIck5XM0o0VTRUYmF2ajNfZ2VVUkxiNnd6dk53MUZOeUFBY25rVGo3WXpUcGNWMWtRcEFONTZ3VDZvSmxZaUt0WU5qN25KbDNp?oc=5","Tue, 22 Sep 2026 12:26:00 GMT","H.C. Wainwright reiterates Armata Pharmaceuticals stock rating on phage data Investing.com UK","Investing.com UK",{"title":212,"link":213,"pubDate":214,"description":215,"source":210},"Armata receives $3.7m DoW funding for phase 3 drug trial - Investing.com UK","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMitgFBVV95cUxOOU1aenJXRFl5dk5CbkF3YVV5dlhqR2pFWHRkcWJsUk0xWGhzVVJhZVJxN052V05pYndhUnFWT2o5d29xeUNVTVNYcHNWNFV6LUpybzRrSjZOdnJQUjllVW1lZ1J6cTRVdDlrRmhHaTFTYUpvSUNlNy0tMVNmbnJsbHZyaTNpemVMTHFkZkI0bHhuUk5VMFVURHlHQVg5OVhCaEpTMWFveFF5dHRiRmI1WGJDRGZNQQ?oc=5","Wed, 23 Sep 2026 11:06:00 GMT","Armata receives $3.7m DoW funding for phase 3 drug trial Investing.com UK",{"title":217,"link":218,"pubDate":219,"description":220,"source":187},"JonesTrading Reaffirms Their Buy Rating on Armata Pharmaceuticals (ARMP) - The Globe and Mail","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMi5gFBVV95cUxNVWtkVUI5MHZ5MmhpQ3JjUHhIU2ZWSkYzUkNmSWV2NWJDTDlPc1BQRjR3ZG94bkxtR1Q0MDd2NDQzMVd1ZlJGcmZRNjREY0hKdklnVTBPNXVMYnJJcXJYRC1ZRWg1bmNpdlZUU0hUdURJeFdvajdKUzBoUHdFRUdBMzBiNXlSREo4UlBWQ0Y1SUxKMmlYR0FOVDAxWUladm55UmExdlpTdUZpaWdkQTdfOFZHc2c5MlM1SHU1Vl9WdEZtaG4ycGtsNHJ5YW12NnBqTVlWdnJLQVh1LUJFaG50X3pzbnJLQQ?oc=5","Mon, 28 Sep 2026 14:48:00 GMT","JonesTrading Reaffirms Their Buy Rating on Armata Pharmaceuticals (ARMP) The Globe and Mail"]